Improved detection of cholangiocarcinoma in high risk patients by biomarker analyses of small amounts of bile

From left: HM Vedeld, MM Grimsrud, T Folseraas, GE Lind
From left: HM Vedeld, MM Grimsrud, T Folseraas, GE Lind

Primary sclerosing cholangitis (PSC) is a progressive chronic liver disease associated with increased risk of cholangiocarcinoma; a highly deadly malignancy that arises in the bile ducts. Due to nonspecific presenting features and overlapping findings in malignant and benign disease progression in PSC, the diagnostic accuracy for cholangiocarcinoma in PSC is low. Consequently, cholangiocarcinoma is commonly detected at advanced stage where most patients have a poor chance of surviving, making cholangiocarcinoma the most common cause of death among patients with PSC.

Publication from The Norwegian Cancer Genomics Consortium in Genome Medicine

Anita Sveen and Bjarne Johannessen
Anita Sveen and Bjarne Johannessen

Project group leaders Anita Sveen and Bjarne Johannessen at Department of Molecular Oncology at the Institute for Cancer Research are 1st and 2nd authors of a major work presenting the ”expressed mutation dose” as a determinant of the functional consequences of mutations in colorectal cancer.

The article - entitled "The expressed mutational landscape of microsatellite stable colorectal cancers" is published in the journal Genome Medicine.

Novel gene expression-based classification of metastatic colorectal cancer published in Genome Medicine

S. Hossein Moosavi, 1st author
S. Hossein Moosavi, 1st author

The multidisciplinary team of the K.G.Jebsen Colorectal Cancer Research Centre publishes a novel gene expression-based classification of metastatic colorectal cancer.
PhD student S. Hossein Moosavi in Anita Sveen’s project group at the Dept. of Molecular Oncology at the Institute for Cancer Research is 1st author of this paper published in Genome Medicine.
This is the first large study of multi-metastatic gene expression profiling of colorectal cancer liver metastases, and the new metastasis-oriented subtyping framework showed prognostic relevance in the context of tumor heterogeneity. 

Ragnhild Lothe awarded the Excellent Researcher Award at the Oslo University Hospital

From the ceremony: Vietri, Lothe and Pihlstrøm.
From the ceremony: Vietri, Lothe and Pihlstrøm.

Three Oslo University Hospital scientists received prestigous awards for their outstanding research on August 27th. The major prize - the "Excellent Researcher Award" - went to Ragnhild A. Lothe. Lasse Pihlstrøm and Marina Vietri both received the "Early Career Award".
The prize money - 300.000 and 150.000 NOK respectively - is earmarked for research activities.

The ceremony was streamed and is available via YouTube.

Anita Sveen awarded the ICR "Researcher of the Year" Prize for 2020

Anita Sveen (photo: Per M. Didriksen)
Anita Sveen (photo: Per M. Didriksen)

Anita Sveen (39) – senior researcher and project group leader at Institute for Cancer Research – was on December 16th awarded the prize Researcher-of-the-Year from the leadership at ICR for her outstanding scientific contributions. The award of 100 000 NOK is financed by the Radium Hospital Foundation (Radiumhospitalets legater) and is a personal scholarship for stimulating further excellence in research. 

Three new academic degrees defended at Faculty of Medicine and Faculty of Mathematics and Natural Sciences, University of Oslo, by members of the Dept of Molecular Oncology

Tuva Høst Brunsell with main supervisor Arild Nesbakken.
Tuva Høst Brunsell with main supervisor Arild Nesbakken.

In June, Tuva Høst Brunsell (MD) digitally defended her PhD “ Heterogeneity of prognostic biomarkers in colorectal liver metastases”, Institute for Clinical Medicine, University of Oslo. The thesis includes three papers (Brunsell et al., Clin Colorectal Cancer 2020; Brunsell et al., Eur J Surg Oncol 2019; Berg*, Brunsell* et al., submitted).

On September the 4th, Christer Anker Andreassen, digitally defended his MSc, Institute of Biosciences, University of Oslo. “The functional and clinical impact of the E3 Ubiquitin ligase NEDD4 in colorectal cancer and its role in regulating PTEN and P53”.

On September the 11th, Mikael Ravndal, defended his MSc, Department of Informatics, University of Oslo. "Algorithms for exploring heterogeneity in prostate cancer patients from RNA-seq data".

TP53 proficient colorectal cancer cells are sensitive to PARP inhibition

Jørgen Smeby (left) and Kushtrim Kryeziu are shared first authors
Jørgen Smeby (left) and Kushtrim Kryeziu are shared first authors

By examining vulnerabilities in colorectal cancer, Jørgen Smeby, Kushtrim Kryeziu, and colleagues demonstrated the efficacy of PARP inhibitors for a subgroup of colorectal cancer cell lines in a recent paper in EBioMedicine (The Lancet’s open access).

The cancer patient’s own drug sensitivity model

From left: Eide, Kryeziu and Bruun.

The cancer patient’s own drug sensitivity model: researchers from the Lothe lab and collaborators recently published a paper in Clinical Cancer Research describing ex vivo patient-derived organoids from colorectal liver metastases in a heterogeneity context. 

Drs. Jarle Bruun, Kushtrim Kryeziu and Peter W. Eide (photo) were shared 1st authors , and have established the PDO lineages and drug screen analyses.

Jørgen Smeby the first to defend his PhD digitally at the Institute for Cancer Research

Jørgen Smeby during the digital PhD defence

The first digital PhD defence at the Institute for Cancer Research was held on the 20th of April 2020.

Dr. Jørgen Smeby defended his thesis "Molecular subtype-dependent impact of driver mutations in colorectal cancer" submitted to the Faculty of Medicine, University of Oslo.

The work was performed in the Lothe lab at the Institute for Cancer Research. 

Scientific achievements at Dept Molecular Oncology in 2019

As we enter a new year, we can look back on our scientific achievements in 2019. Dept Mol Oncol is one of six research departments at the Institute for Cancer Research, and we account for about 10% of the total staff (full-time equivalent). Harvesting from a positive working environment and active collaborations among our three research groups, we can document an upward trajectory in the volume, citation numbers, and impact of our research publications.

Feb 2020Dec 2019Nov 2019Sep 2019Aug 2019Jun 2019Oct 2018Jun 2018Mar 2018Jan 2018Nov 2017Aug 2017Jun 2017Apr 2017Aug 2016Jun 2016Mar 2016Feb 2016Dec 2015Nov 2015Sep 2015Aug 2015Jun 2015May 2015Feb 2015Dec 2014Nov 2014Sep 2014Jul 2014May 2014Apr 2014Dec 2013Nov 2013Sep 2013May 2013Apr 2013Oct 2012Aug 2012Mar 2012Feb 2012Jan 2012Nov 2011Jun 2011May 2011Apr 2011Dec 2010Nov 2010Jun 2010May 2010Mar 2010Feb 2010Nov 2009Jun 2009May 2009Jan 2009Dec 2008Nov 2008Oct 2008Sep 2008Aug 2008Jun 2008May 2008Apr 2008